CAS: 2227480-51-3

Applications Ponatinib N-Oxide is derived from Ponatinib (P688250), which is a tyrosine kinase inhibitors (TKI) and used to treat chronic myeloid leukemia (CML) (1,2,3). Ponatinib is also used in combination with other drugs, such as forskolin, to combat TKI resistance in patient with CML (3), targeted drug in small-cell lung cancer. Potent FAK inhibitor. FGFR/VEGFR/Bcr-Abl inhibitor. It is a COVID19-related research product. References De L., et al.: J. Pharmacol. Exp. Ther., 363, 12-19 (2017), Arts, F. A., et al.: Hum. Mol. Genet., 26, 1801-1810 (2017)